Regulatory
First New Treatment in 70 Years: FDA Approves Gazyva to Prevent Nephrotic Syndrome Relapses
Children with idiopathic nephrotic syndrome have relied on steroids since the 1950s. Roche’s obinutuzumab is now approved to keep frequently relapsing patients in remission — offering a way off repeated steroid courses.